Jens K. Habermann received his training as Medical Doctor at the University of Lübeck, Germany. He obtained his Ph.D. at the Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden, and received a postdoctoral fellowship at the National Cancer Institute, NIH, Bethesda, USA. In 2012, Jens K. Habermann received his Professorship at the University of Lübeck and University Hospital Schleswig-Holstein, Campus Lübeck, Germany. He works clinically as board certified specialist in human genetics, is Head of the Laboratory for Translational Surgical Oncology and Biobanking, Scientific Director of the University Cancer Center Lübeck, and University representative and Head of the Interdisciplinary Center for Biobanking-Lübeck (ICB-L). Combining clinical routine, biobanking, and cancer research, he focuses to optimize individualized medicine by targeting tumor heterogeneity and applying liquid biopsies.
Jens K. Habermann has become ESBB member after participating at the ESBB inauguration meeting in Marseille 2011. He has served as Councillor before being elected as President-Elect. Jens K. Habermann is currently President of ESBB. He is also Board Member and Representative of the German Biobank Alliance (GBA).
Rosita Kammler is Head of Translational Research Coordination for the International Breast Cancer Study Group (IBCSG) and the European Thoracic Oncology Platform (ETOP). Her work has revolved around clinical trial biobanking, translational research coordination and project management for the past 17 years. She has provided leadership for designing, building and conducting the translational research programs and biobanks for IBCSG and ETOP, enabling state-of-the-art oncology research. She is responsible that the trial biosamples meet the objectives for quality, quantity, ethical use, to ensure the integrity of research data and analysis. These biobanks have been a critical resource for the more than 40 translational research studies conducted by IBCSG/ETOP, or collaborators. She is responsible for the management and oversight of all translational research activities and biobanking activities conducted by IBCSG and ETOP in the course of prospective clinical trials and retrospective biomarker analyses, including the ETOP Lungscape and Mesoscape iBiobanks.
Rosita Kammler trained in international business management. Her biobank management expertise includes knowledge of international regulatory implications for sample use and transfer, development of patient informed consent forms allowing future research use, systems requirements for biobank information systems, and the conduct of quality assessments for biomarker studies.
Rosita Kammler is President-elect of the European, Middle East, & African Society for Biopreservation and Biobanking (ESBB).
Dr Balwir (Bal) Matharoo-Ball has a wealth of experience in academic research as well as the NHS. Bal has worked for the Nottingham Health Science Biobank (NHSB) since January 2011 and is currently the Deputy Director. In this role her principal interests have been to align the resources of the NHS, as a single service provider, and provide a unique platform for translational and stratified medicine in the UK. Part of this initiative has been a novel policy of the co-evolution of biobanking and informatics resources within the NHS. Bal is Chair of the NHSB Access Committee and Ethics and Public Patient Involvement (PPI) lead and a member of the PPI Strategy Board for Nottingham University NHS Trust. She is also a co-applicant on the national virtual Breast Cancer Now Tissue Bank initiative which has secured over £3 million in grant funding. Bal has been a member of European, Middle Eastern and African Society for Biopreservation and Biobanking (ESBB) and also International Society for Biological and Environmental Repositories (ISBER) since 2012. For the past 3 years Bal has been a member and actively contributed of the ESBB Programme committee. Recently Bal was been given the delightful position to be Chair of the ESBBtranslate working very closely with Dr Christina Schroeder and Dr Oliver Gros from Fraunhofer Institute in Germany. Bal is also a reviewer for the Biopreservation and Biobanking journal.
Jeanne-Hélène di Donato has been involved in biobanking for the past 20 years, first as manager of the French AFM-Généthon biobank for a period of 14 years, then since 2005 as a consultant for biobanks in 3C-R Company. During this time, she has worked on establishment of best practices for BRCs as member of the French delegation for the OECD BRC Task Force and leader of the working group on best practice guidelines on human-derived material. She has also worked on the quality management system for BRCs as member of French commission for the publication of Standard NF S 96-900: BRC quality, which is the French standard alongside ISO 9001-2008 for biobank certification. She is a certificated auditor for ISO 9001 quality management. In addition she has worked on ethical issues relating to research use of human samples and is a member of an ethics committee for biological research. Also on the organisation of biobank activities with respect to logistic, administrative and legal issues. She is an expert on collections and biobanks for several French ministries, cancer organisations, and for her consulting clients. She has been involved in establishing and managing the Eurobiobank network since 2001 and in founding and managing the 3C-R Club, which is a francophone network of 83 BRCs established to promote discussion, collaboration and problem solving. Her involvement in ESBB began from the very beginning of this network and was the first individual member! She is involved in a variety of ESBB activities, including production of the English summary of her Cahier 3C-R reports for the members-only website, and has been a member of the review panel for the Research Biobank of the Year Competition (RBYC).
Since the Leipzig Research Center for Civilisation Diseases (LIFE) was set up 2010, I've been active in the interesting field of biobanking. Now I'm head of the LIFE-Biobank and preanalytical laboratory.
My personal experiences in biobanking have concentrated on quality assurance of biological samples in biobanks, biobank management and education. I'm a member of the expert committee working group in the German Institute for Standardization (DIN) which supports the ISO TC 276 responsible for the coming new ISO norm 20387 on biobanking and BBMRI-ERIC QM workgroups 3 and 4 for the evaluation of CEN standards. I also participated in quality workshops of BBMRI.de, which produced generic standard operating procedures. As part of the Steering Committee of the new "German Biobank Alliance" (GBA) initiated and coordinated by BBMRI.de we try to link GBA biobanks to the BBMRI-ERIC infrastructure for the cross-border exchange of biosamples and related data. To do so harmonization between GBA and BBMRI-ERIC is needed especially in IT networking, common quality standards and measurements as well as ELSI regulations.
Dr Dominik Lermen is Group Manager Biomonitoring & Biobanking at Fraunhofer IBMT and is based in Sulzbach, Germany. He received his PhD in stem cell biology from the University of Trier in association with the Fraunhofer Institute for Biomedical Engineering IBMT, and the German Research Foundation (DFG). His aim has always been to support activities that focus on protection of the environment and human health. Besides being involved in biodiversity related activities, human biomonitoring (HBM), the health-related surveillance of chemicals and environmental pollutants in human tissues and body fluids, is the main focus of his scientific work.
Dominik has been involved in the environmental division of the German Environmental Specimen Bank (ESB) since 2002. He became a regional manager of the Cryo-Brehm, the German Cell Bank for Wildlife in 2010 and has led the IBMT working group Biomonitoring & Biobanking since 2012 and has been head of the Fraunhofer IBMT branch Münster (North Rhine Westphalia, GER) since 2016. On behalf of the German Environment Agency he oversees two major biobanks for human biomonitoring in Germany, the German Environmental Specimen Bank (ESB) and the biobank of the German health related Environmental Survey (GerES).
Dominik is an active member of both ESBB and ISBER and in the past he has co-chaired the programme committees on behalf of both organisations.
Dr. Maimuna Mendy is a molecular virologist by training over 25 years’ experience in research on hepatitis infection and liver disease in SS Africa. She has a background in capacity building and infrastructure in Low and Middle Income Countries (LMIC) in the area of biobanking and laboratory with expertise in coordinating studies that involve multiple international partners.
She retires as Head of the International Agency for Research on Cancer (IARC) LSB Group in Sep 2017. The IARC Biobank is one of the largest international biobanks. Dr Mendy organized its centralization which brought together diverse collections from multiple collaborative studies onto a single platform and ensuring that best practice principles and international ethical guidelines are followed for the management and re-distribution of the resources.
She founded the Biobank and Cohort Building Network for LMIC (BCNet) in 2013 to provide technical and scientific support to LMIC biobanks on issues related to quality, infrastructure, transnational access to biological resources and ethical implications.
Dr Mendy Joined ESBB from its inception, a member of the Africa and the Education and Training Working Groups. She has published widely and co-author to over 70 publications in peer review journals.
She is a member of several international organisations and member of a number of Advisory Boards
Sofie Bekaert is currently Manager Translational Program at the Flemish Interuniversity Institute for Biotechnology (VIB), where she coordinates the Grand Challenges Program and part-time senior lecturer at the Faculty of Medicine and Health Sciences from Ghent University.
Prof. Sofie Bekaert was trained as a doctor in Applied Biological Engineering. After 10 y of research, setting up a research platform on biological aging, next generation sequencing and biomarkers, she became valorization and innovation manager at Ghent University. In 2010 she initiated the Clinical Research Center at Ghent University Hospital. As the head of Bimetra, she had the responsibility over a dedicated team in the daily management of the central point of contact for facilitation of different aspects of translational biomedical research (ethico-legal aspects, datamanagement and monitoring of clinical trials, research and innovation management within the hospital, biobanking, big data).
Prof. Bekaert is liaising to strategic translational initiatives concerning biobanking and clinical research and innovation, both at the regional and (inter)national level. Between 2017-2019 she was appointed president of the Board of directors of the BBMRI.be, the Belgian node within the European biobank infrastructure network and she is involved in multiple societal valorization projects concerning stakeholder involvement and participation in research (e.g. Eupati, King Baudouin Foundation – multistakeholder dialogue for prioritization of research).
Ayat Salman is a doctoral student at McGill University in the Department of Family Medicine and a consultant in biobanking sciences. She received her Bachelor’s Degree in Anatomy and Cell Biology and her Masters Degree in Experimental Surgery from McGill. Her experience includes 10 years of clinical research experience, as a clinical research associate and 6 years of managerial experience with the HPB/Transplant Clinical Research Group at the McGill University Health Centre (MUHC). She has been a lead expert at the MUHC in Biobanking since 2011. She has established multiple biobanks within the MUHC since 2011. She is currently the Chair of the ISO 276 (Biobanking and Biotechnology) Mirror Committee within the Standards Council of Canada. She is also a member as well as ex-officio member of the ESBB Council since 2013 and now A Councillor since Spetember 2018. She is also co-chair of the Communications Committee at ISBER and Chair of the Social Media Working Group of ESBB. Her area of expertise focuses on the evaluation of biobanks in primary care within Quebec.
Since January 2015 Kirstin has been at AstraZeneca to take in the role of Principal Scientist: Human Biological Sample Governance and Strategy. Kirstin works with the biobanks globally to ensure that AstraZeneca scientists can access the samples and data that they need in a compliant.
Kirstin has worked in the Biobanking field for over 15 years in different roles and sectors and has watched the field grow and develop. Kirstin graduated in Physiology and Pharmacology (BSc) and completed her PhD on asthma research at Southampton University. She carried out Post-Doctoral research in to Muscular Dystrophy at King’s College and Imperial College, before managing the UK Parkinson’s Disease Society Tissue Bank at Imperial College from 2002, until 2009. Dr Goldring worked at UCL from 2009-2012 as the Biobank facilitator. The role involved in developing biobank infrastructure and support, and providing advice on protocols, ethics and regulations for use of human samples. From 2012, the role expanded to co-ordinate the UCL BioResource, aiming to develop a panel of healthy volunteers and patients consent for recall to future research studies.
At UCL she was responsible for supporting the co-ordination of the successful bid from UCL and Nottingham to the MRC to host the UKCRC Joint Funders Tissue Directory and Coordination Centre. This Centre is an important initiative to bring together Biobanking in the UK, and is now the UK hub of BBMRI and I now represent Pharma on the steering committee. I sit as the external representative on the Human Materials and Data Management Committee (HMDMC) at the Sanger Institute as well as being a member of the Ethics Advisory Committee for EURIPRED. Over recent years she has participated in and with Daniel Simeon-Dubach and Marianne Henderson chaired sessions on Sustainability at ESBB and ISBER meetings, leading to publications. She is also part of the Pharma working group of ISBER.
Rolf Morset is a Sales Manager Life Sciences for Europe & Africa at Worthington Industries. A leading manufacturer of secure cold chain sample storage, transportation and data management for the Life Sciences Market.
He is an experienced Sales & Marketing Manager, with a strong background in building sales organizations with P&L responsibility in a variety of functions and different retail & B2B markets. His core competencies are: Business management, Sales & Marketing strategy, New Business Development, People Management, Cross Cultural, Change Management, Strategical thinking, integrity and loyalty. He became an ESBB member 7 years ago and has been involved for several years within ESBB, amongst others as Vendor Committee Chair, Councilor and member of the program committee of EBW in Luebeck 2019.
Mark Divers is director of Karolinska Institutet Biobank, in Stockholm, Sweden, where he has led the implementation of large-scale biobanking for ten years.
He has a background of 25 years in the pharmaceutical industry most of which was involved in building, leading and developing R&D infrastructure to serve medical research.
He has a PhD in the molecular biology of antibiotic resistance in hospital bacteria, and has also researched on the molecular biology of antibiotic production.
His current interest is in the impact and value of biobanking in human health.
Veronique T’Joen is Biobank Manager of the Bioresource center Ghent. She obtained her Master degree in Biomedical Sciences in 2006, with a specialization in tissue engineering and regenerative medicine. She worked two years as a process engineer for the Red Cross tissue banks (Cord blood and stem cell banks). Subsequently, she earned a PhD further specializing herself in cell culture techniques (hESC) and cryopreservation/thawing techniques. Since 2012, she is the biobank manager at Ghent University Hospital. She has set up a central state-of-the-art biobanking facility and implemented a quality management system (peer reviewed) for high quality biobanking. She is an expert in operational biobank planning (sample flows, collection, storage, distribution) and related data management (BIMS system), quality management (national and international biobank guidelines, CEN/TS standards, ISO standards) and ethical-legal issues.
Laurent Dollé is a scientist in Biomedical Sciences with 16 years of experience in Cell Biology, Physiology and Molecular Biology enriched with high expertise in standardization, quality requirements and business strategy. In 2012 Laurent became Assistant Professor at the Free University of Brussels. Since 2016, Laurent, as operating manager, leads the biobanks network from Wallonia-Brussels regions (BWB) with talent, allowing him to accumulate a profound knowledge on the vast ecosystem of biobanking (collection, harvesting, storage, distribution, all compliant with international quality standards (GLP/GMP/GCP and ISO standards)). Ever since, his field of expertise also pertains to the legislation regarding the use of human material, both for therapeutic and scientific purposes and he also gained robust expertise in ethics, clinical trials and medical devices. Since September 2017, Laurent became managing director at BWB, and very recently, President of the Belgian Node BBMRI.be.
Loes Linsen is a Master in Biotechnology and obtained a PhD in Biomedical Sciences from Hasselt University. Loes entered the biobank world in 2008. She became biobank manager of the University Biobank Limburg (UBiLim), where she set up the organizational structure (a collaboration of 3 independent institutions with a biobank facility on each site), including the ethical/legal procedural framework, integration of the quality management system into ISO15189 accreditation and implementation of the Biobank Information Management System Lab vantage. In that period, she participated in the European FP6 project “Cancer Control using Population-based Registries and Biobanks”. Loes also contributed to the setup of the Flemish Biobank, including auditing for the regional biobank audit programme. Since 2016 Loes is a staff member of the Biobank University Hospitals Leuven, where she continues to facilitate all things biobanking from a (biospecimen) quality-oriented perspective. Loes is a member of ESBB, ISBER and the ISBER biospecimen research workgroup, as well as several expert working groups of bbmri-eric and bbmri.be.